by TractManager | Aug 19, 2019 | Emerging Technology Report
Rozlytrek (entrectinib) is an oral tumor-agnostic agent intended to selectively inhibit the tyrosine kinase activity of TRKA, TRKB, TRKC, and ROS1 (ROS proto-oncogene 1 receptor tyrosine kinase) rearrangements. Rozlytrek is indicated for the treatment of adult and...
by TractManager | Aug 6, 2019 | Emerging Technology Report
Sunosi is an oral phenylalanine-derived selective dopamine and norepinephrine reuptake inhibitor (DNRI). Norepinephrine inhibits rapid eye movement sleep and promotes wakefulness. Dopamine plays a role in areas of the brain responsible for sleep regulation. Sunosi is...
by TractManager | Aug 6, 2019 | Health Technology Assessment
Health Problem: Autism spectrum disorder (ASD) is a neurodevelopmental condition that presents in childhood and is characterized by persistent deficits in social communication and social interaction; restricted, repetitive patterns of behavior, interests, or...
by TractManager | Aug 6, 2019 | Emerging Technology Report
Sunosi is an oral phenylalanine-derived selective dopamine and norepinephrine reuptake inhibitor (DNRI). Norepinephrine inhibits rapid eye movement sleep and promotes wakefulness. Dopamine plays a role in areas of the brain responsible for sleep regulation. Sunosi is...
by TractManager | Aug 5, 2019 | Emerging Technology Report
Turalio (pexidartinib) is an oral small molecule kinase inhibitor of colony stimulating factor-1 receptor (CSF1R) for treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations, and...
Recent Comments